WHY PERFUSABLE VASCULATURE MATTERS
Without flow, in vitro models fall short.
Models without perfusable vessels lack oxygen and nutrients, leading to early cell death and limited translational relevance.
Flow is critical to studying drug delivery, immune response, and metastasis in realistic 3D tissue environments.
Fluorescence video of our 3D vascularized tissue model perfused with FITC-Dextran, demonstrating flow through our complex vasculature network. Scale bar: 200 µm.
supported flow systems
Our models come ready-to-use in Ibidi microfluidic chips, fully compatible with standard imaging setups and a variety of flow systems, including unidirectional and bidirectional configurations.
PERISTALTIC pUMP
Continous, programmable flow
.png)
rOCKER pLATFORM
Gentle, oscillatory motion
SYRINGE pUMP
Precise, low-volume dosing
FUNCTIONAL VASCULATURE
WITH MARKER-STAINED ENDOTHELIum
By incorporating endothelial cells into our 3D vascular networks, we create functional vessels validated by marker expression and biomimetic architecture.
.png)
LEFT: 3D bioprinted vasculature lined with HUVECs, cultured under continuous flow for 7 days.
RIGHT: Region of interest showing endothelial marker expression: DAPI (blue), ZO-1 (green), and CD31 (red), confirming proper HUVEC attachment and morphology. Scale bar: 50 μm.
triple negative breast CANCER
An aggressive cancer subtype that lacks 3 key receptors, triple-negative breast cancer does not respond to hormone therapy and accounts for ~15% of invasive breast cancer. Partnership in progress to evaluate nanoparticle-enhanced radiation therapy and treatment outcomes (learn more here).
Real-Time Insights into Tumour Behaviour and Validated Dose-Response IN BREAST CANCER MODELS
DAY 0
DAY 4
Dosed with Paclitaxel
DAY 7
End Point
Assay Readout
LIVE/DEAD
DAPI/Ki67
Drug dosing & functional readouts in 3D triple-negative breast cancer vascularized models.
TOP: Experimental timeline for drug dosing and endpoint analysis.
MIDDLE: Paclitaxel-treated vascularized tissues demonstrate successful vessel perfusion following FITC-dextran injection.
RIGHT: Viability/proliferation analysis via Live/Dead (top right) and Ki67 (bottom right) staining.
Scale bars = 200 µm.
NON-SMALL CELL LUNG CANCER
Non-small cell lung cancer accounts for 80–85% of all lung cancer cases, making it the most common lung cancer subtype. Partnership in progress for T-cell screening and immunotherapy (learn more here).
Tumour Growth and Immune Cell Infiltration IN LUNG CANCER MODELS
NCI-H460 cells were bioprinted into 3D non-small cell lung cancer vascularized models and cultured for 7 days.
LEFT: Tumour spheroid formation is shown in Brightfield (5X)
MIDDLE: Ki67+ staining indicates active proliferation.
RIGHT: CD8+ T cell infiltration visualized in fluorescence (CellTracker Green CMFDA). Scalebars = 200 µm.
SCIENTIFIC POSTER — Validation of bioprinted Vascularized Tumour Models
_edited.png)
This study aims to demonstrate that VoxCell’s bioprinted, vascularized tumour models can generate reliable efficacy readouts using the clinically approved anticancer drug Paclitaxel, alongside the development and validation of a tumour model for immunotherapy screening.
BUILDING THE NEXT-GENERATION
IN VITRO VASCULARIZED MODELS
We are seeking partners for our 3D vascularized tissue models with custom use cases in disease modeling and drug development.
complete
building
next
Perfusable In Vitro
Vascularized Models
Models with built-in, perfusable vasculature and vascular complexity.
Establishing Endothelial Function in Models
Incorporating endothelial cells into vasculature, to create functional vessels.
Advancing Model Complexity
Advancing model fidelity through stromal and immune integration.
